Doctor Mario Luca Morieri graduated (cum laude) at the Medical School of the University of Bologna (Italy), and completed his residency in Internal Medicine at the University of Ferrara (Italy), focusing his clinical and research activities in the field of prevention of cardiovascular and metabolic disease. Prompted by his interest in precision medicine in 2015 he joined Dr. A. Doria group at the Joslin Diabetes Center (Boston, USA) to work on the genetic modulators of CVD-preventing interventions in type 2 diabetes. This successful collaboration is still ongoing (recently he was appointed as Visiting Research Associate at Joslin Diabetes Center) and in 2018 he moved to the University of Padova, Department of Medicine (where he completed a PhD program in Traslational medicine). Doctor Morieri is currently a Research Associate at the University Hospital of Padova and his ongoing activities are focused on precision medicine studies aiming to leverage genetics, and real-world data, to improve treatment and care of patients with diabetes and dyslipidemia. He is the Principal Investigator of a pharmacogenetic randomized clinical trial evaluating how genetic variants can help identifying subjects with better response to cardiovascular preventive treatments in patients with type 2 diabetes. He has produced several scientific contributions, published in the top-ranked journal in the field (e.g. NEJM, Diabetes, Diabetes Care).